Konrad Zieliński lost his voice to cancer while a student at the University of Warsaw. After completing a PhD in bionic systems for laryngectomees — people who have had their larynxes removed — he launched Uhura Bionics in 2023 to develop noninvasive wearable speech devices. The startup, selected for TechCrunch Disrupt 2026's Startup Battlefield 200, offers two models including a high-end version called Whitney that aims to restore emotional expression such as laughter, shouting and singing. Zieliński will demonstrate the device at Disrupt in October and at SF Tech Week, where he plans to sing onstage.
Zieliński's devices avoid the flat, robotic sound of traditional handheld speaking aids and the maintenance burdens of surgically implanted voice prostheses. "I'm satisfied with what I've built because you added the emotional layer," he said, speaking with intonation and a slight electronic undertone.
The basic model costs $500 and Whitney costs $1,500, both sold as wellness devices paid out of pocket. Uhura is pursuing Class I medical device classification in Europe and later the United States, which would allow partial reimbursement through health insurance. Zieliński estimates the market for laryngectomee devices at about $2 billion and sees potential for expansion into other speech disorders.
Competitors include Atos Medical, an established medical device company, and startup Laronix. Future updates will add higher-pitched voice options for women and personalization features so users do not all sound alike.
Analysis
Why This Matters
- Laryngectomees currently face a choice between robotic-sounding handheld devices and surgical implants that require ongoing care. Whitney offers a noninvasive alternative that preserves emotional nuance, which could significantly improve quality of life.
- The pursuit of medical device classification could make the technology more affordable through health insurance coverage, expanding access beyond those who can pay $1,500 out of pocket.
- If the technology is adaptable to other speech disorders, its impact could extend well beyond the estimated $2 billion market for laryngectomee devices.
Background
Voice loss due to laryngeal cancer or other conditions has traditionally been addressed by electrolarynx devices that produce a mechanical monotone, or by surgical voice prostheses that require regular cleaning and can lead to complications. Zieliński, himself a laryngectomee, focused his PhD research at the University of Warsaw on bionic systems for this population, leading to the wearable, noninvasive approach now commercialised as Uhura Bionics.
Key Perspectives
Konrad Zieliński (Founder/User): Having personally experienced voice loss, he emphasises restoring emotional expression. He draws an analogy to corrective glasses: a simple, everyday wearable that becomes unobtrusive. "I'm satisfied with what I've built because you added the emotional layer," he said.
Competing Technologies (Atos Medical, Laronix): Existing players offer modern alternatives, but the market is still dominated by older, less expressive solutions. Uhura's differentiation lies in its noninvasive design and emotional range.
Regulators and Payers: Currently classified as wellness devices, the products are paid out of pocket. Achieving Class I medical device status in Europe and the U.S. is a critical step toward insurance reimbursement and broader adoption.
What to Watch
- The startup's live demonstration at TechCrunch Disrupt (October 13-15) and SF Tech Week, where Zieliński will sing onstage.
- Progress toward European and U.S. medical device classification.
- Release of higher-pitched voice options for women and personalisation features.